Gut microbiota: new perspective on the treatment of acute pancreatitis and clinical application prospects.
10.3760/cma.j.cn121430-20240903-00744
- Author:
Qun LANG
1
,
2
;
Yujie ZENG
;
Hua YAO
;
Ninan DAI
;
Xiaoyun FU
;
Bao FU
Author Information
1. Department of Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China. Corresponding author: Fu Bao, Email: fubao0607@
2. com.
- Publication Type:English Abstract
- MeSH:
Humans;
Gastrointestinal Microbiome;
Dysbiosis;
Pancreatitis/microbiology*;
Fecal Microbiota Transplantation;
Probiotics/therapeutic use*;
Acute Disease;
Anti-Bacterial Agents/therapeutic use*;
Enteral Nutrition
- From:
Chinese Critical Care Medicine
2025;37(9):797-801
- CountryChina
- Language:Chinese
-
Abstract:
Acute pancreatitis (AP) is a severe inflammatory disease characterized by self-digestion of pancreatic tissue and inflammatory responses. Recent studies have revealed a close connection between gut microbiota and AP. The gut microbiota community, a complex ecosystem composed of trillions of microorganisms, is closely associated with various physiological activities of the host, including metabolic processes, immune system regulation, and intestinal structure maintenance. However, in patients with AP, dysbiosis of the gut microbiota are believed to play a key role in the occurrence and progression of the disease. This dysbiosis not only impairs the integrity of the intestinal barrier, but may also exacerbate inflammatory responses through multiple mechanisms, thereby affecting the severity of the disease and patient' clinical prognosis. This article reviews the mechanisms of action of gut microbiota in AP, explores how gut microbiota dysbiosis affects disease progression, and evaluates current clinical treatment methods to regulate intestinal flora, including probiotic supplementation, fecal microbiota transplantation, antibiotic therapy, and early enteral nutrition. In addition, this article discusses the efficacy and safety of the aforementioned therapeutic approaches, and outlines future research directions, aiming to provide novel perspectives and strategies for the diagnosis, treatment and prognostic evaluation of AP. Through in-depth understanding the interaction between gut microbiota and AP, it is expected that more precise and personalized therapeutic regimens will be developed to improve patients' quality of life and clinical outcomes.
